Short Bowel Syndrome Pipeline — VivoSeq

A Phase 3, Double-blind, Randomized, Parallel Group, Placebo-controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice Weekly, Followed by a Long-term, Open-label Safety Evaluation in Patients With Short Bowel Syndrome-intestinal Failure (SBS-IF)

Recruiting· Zealand Pharma logo

Zealand Pharma·Phase 3·NCT07197944·90 enrolled

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

Recruiting·EEclipse Regenesis, Inc.·Preclinical·NCT05535361·40 enrolled

A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 (Sonefpeglutide) in Adult Subjects With Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)

Recruiting· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 2·NCT04775706·18 enrolled

A Parallel-group Treatment, Phase 3, Double-blind, Randomized, 2-arm Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)

Recruiting·VVectivBio AG·Phase 3·NCT07742735·124 enrolled

A 90 Day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children With Short Bowel Syndrome Who Are Dependent on Parenteral Nutrition

Recruiting·BBoston Children's Hospital·Preclinical·NCT03530852·32 enrolled

A Randomized, Double-blind, Crossover, Placebo-controlled Phase IIa Clinical Study Evaluating the Efficacy and Safety of Recombinant Acylated Glucagon Like Peptide-2 Analog (FT1) for Injection in Patients With Short Bowel Syndrome

Recruiting·CChongqing Peg-Bio Biopharm Co., Ltd.·Phase 2·NCT07704047·8 enrolled

Phase IV Clinical Study Evaluating Efficacy and Safety of Recombinant Human Growth Hormone Injection for Adult Short Bowel Syndrome

Recruiting· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Approved·NCT07691125·100 enrolled

TED_ORG: Study on Short Bowel Syndrome

Recruiting·MMeyer Children's Hospital IRCCS·N/A·NCT07400783·50 enrolled

Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)

Recruiting·NNapo Therapeutics, S.p.A.·Phase 2·NCT06904872·18 enrolled

Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition

Recruiting·CChongqing Peg-Bio Biopharm Co., Ltd.·Phase 3·NCT06512584·72 enrolled

An Open-label, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of 0.05 mg/kg/Day Subcutaneous Teduglutide Following Treatment of Short Bowel Syndrome for 24 Weeks in Chinese Adults Who Are Dependent on Parenteral Support

Active, not recruiting· Takeda logo

Takeda·Phase 3·NCT06973304·13 enrolled

Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome

Active, not recruiting·LLindsey Russell, MD·Phase 1·NCT06326645·6 enrolled

A 104-week, Multicenter, Open-label, Single-arm, Phase 3 Extension Trial Investigating the Long-term Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Rolling Over From the EASE SBS 2 or 3 Trials

Active, not recruiting· Zealand Pharma logo

Zealand Pharma·Phase 3·NCT07228403·28 enrolled

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

Active, not recruiting·VVectivBio AG·Phase 3·NCT05018286·158 enrolled

A 90 Day Observational Study as an Extension to the Phase 3, Open Labeled, Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children With Short Bowel Syndrome Who Are Dependent on PN

Enrolling by invitation·BBoston Children's Hospital·N/A·NCT05635747·32 enrolled

Short Bowel Syndrome

Pipeline Metrics

Competitive Landscape

Top Companies

Programs by Phase

Modality Breakdown

Trial Status

Trial Activity